1. Zhao Y,Liu X, He Q, et al. Phase II trial of an orelabrutinib-based combination therapy in newly diagnosed primary central nervous system lymphoma. Blood Lymphat Cancer,2025 Dec. Epub（并列第一作者）
2. Yu TS, Han SQ, ...,Liu XG.Effects of orelabrutinib, a BTK inhibitor, on antibody-mediated platelet destruction in pimary imune trombocytopenia. Br J Haematol. 2025 Mar. Epub（通讯作者）
3. Hou XR, Yan ZY, ...,Liu XG. Corticosteroids plus metformin versus corticosteroids as front-line treatment for patients with newly diagnosed ITP and pre-existing type 2 diabetes mellitus: A multicentre propensity score-matched study. Br J Haematol. 2024 Dec 18. Epub（通讯作者）
4. Xu LJ, Zhao YJ, ...,Liu XG. Development and validation of a nomogram for individualizing fall risk in patients with hematologic malignancies. Geriatr Nurs. 2024:60:121-127.（通讯作者）
5. Su YY, Yu YF, ...,Liu XG. Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review. Diagn Pathol. 2024;19(1):122.（通讯作者）
6.Liu XG, Hou Y, Hou M. How we treat primary immune thrombocytopenia in adults. J Hematol Oncol. 2023 Jan 19;16(1):4.
7. Wu HY, Gu CY, ...,Liu XG, et al. Clonal hematopoiesis in unexplained cytopenias. Am J Hematol. 2023 Dec;98(12):E407-E410.（通讯作者）
8.Liu XG, Liu S, Feng Q, et al. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP. Blood. 2016;128(6):852-61.
9. Zhou H, Qiu JH, ...,Liu XG, et al. Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia. Blood. 2014 ;124:3316-9.（通讯作者）
10.Liu XG, Ma SH, Sun JZ, et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcγ receptors on monocytes in patients with primary immune thrombocytopenia. Blood. 2011;117:2061-9.
11. Wang Y, Yu T, ...,Liu X, Peng J, Hou M. Clonal hematopoiesis in primary immune thrombocytopenia. Blood Cancer J,2022 Mar 15;12(3):40.（通讯作者）
12. Yu TS, Wang HY, ...,Liu XG, et al. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv. 2021;5(20):4087-4101.（通讯作者）
13. Yu Y, Hou Y, ...,Liu X, et al. Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. Br J Haematol. 2021;194(1):191-194.（通讯作者）
14. Zhao Y, Xu P, ...,Liu X, et al. Tumor Necrosis Factor-α Blockade Corrects Monocyte/Macrophage Imbalance in Primary Immune Thrombocytopenia. Thromb Haemost. 2021;121(6):767-781.（通讯作者）
15. Yu Y, Wang M, ...,Liu X, et al. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial. Am J Hematol. 2020;95(12):1542-1552.（通讯作者）
16. Wang Q, Zhao Y, ...,Liu X, et al. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. Ann Hematol. 2024;103(3):999-1005.（通讯作者）
17. Dong Q, Li G, ...,Liu X, et al. Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia. Biomed Res Int. 2020;2020:7023168.（通讯作者）
18. Wang YM, Yu YF, ...,Liu XG. The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. Hematology. 2020;25(1):139-144.（通讯作者）
19. Wang Q, Li J, ...,Liu XG. Disrupted balance of CD4 + T-cell subsets in bone marrow of patients with primary immune thrombocytopenia. Int J Biol Sci. 2019;15(13):2798-2814.（通讯作者）
20.Liu XG, Bai XC, Chen FP, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol. 2018;107(6):615-623.
21. Feng R,Liu X, Zhao Y, et al. GPIIb/IIIa autoantibody predicts better rituximab response in ITP. Br J Haematol. 2018;82(2):305-307.（通讯作者）
22. Qu MM, Liu XN,Liu XG, et al. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia. Cytokine. 2017;92:110-117.（通讯作者）
23.Liu XG, Hou M, Liu Y. TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy. Immunol Invest. 2017;46(2):172-182.
24. Liu Y, Wan WZ, ...,Liu XG. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents. Oncotarget. 2017;8(4):7181-7200.（通讯作者）
25.Liu XG, Liu Y, Chen F. Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation. Oncotarget. 2017;8(2):3711-3723.
26.Liu XG, Hou M. Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsed primary immune thrombocytopenia. Open Med (Wars). 2016;11(1):97-100.
27. Liu S, Xiong YZ, ...,Liu XG. Interleukin-17A and -17F Gene Polymorphisms in Chinese Population with Chronic Immune Thrombocytopenia. Ann Clin Lab Sci. 2016;46(3):291-7.（通讯作者）
28. Ge J, Yu YZ, ...,Liu XG, et al. IL-17A G197A gene polymorphism contributes to susceptibility for liver cirrhosis development from patients with chronic hepatitis B infection in Chinese population. Int J Clin Exp Med. 2015;8(6):9793-8.（通讯作者）
29. Liu Y, Zhang DT,Liu XG. mTOR Signaling in T Cell Immunity and Autoimmunity. Int Rev Immunol. 2015;34:50-66.（通讯作者）
30.Liu X, Hou Y, Peng J. Advances in immunopathogenesis of adult immune thrombocytopenia. Front Med. 2013;7(4):418-24.
31.Liu XG, Ren J, Yu Y, et al. Decreased expression of interleukin-27 in immune thrombocytopenia. Br J Haematol. 2011;153:259-67.
32.Liu XG, Li JL, Qin P, et al. Determination of platelet-bound glycoprotein-specific autoantibodies by flow cytometric immunobead assay in primary immune thrombocytopenia. Eur J Haematol. 2011;86:339-46.
33. Zhang L, Li JM,Liu XG, et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid Arthritis. J Clin Immunol. 2011;31(4):606-14.（并列第一作者）
34.成人原发免疫性血小板减少症诊断与治疗中国指南（2025年版）中华血液学杂志2025.（执笔人）
35.成人原发免疫性血小板减少症诊断与治疗中国指南（2020年版）中华血液学杂志2020；41（8）：617-623.（执笔人）
36.刘新光，侯明。成人原发免疫性血小板减少症研究与诊治国际共识报告更新（2019版）解读。中华血液学杂志2020；41（2）：89-92.
37.刘新光，侯明。成人原发免疫性血小板减少症：2019版美国血液学会指南与国际共识报告更新解读。中华血液学杂志2020；41（6）：441-445.
